WO1998046612A1 - Process for synthesizing phosphodiesters - Google Patents
Process for synthesizing phosphodiesters Download PDFInfo
- Publication number
- WO1998046612A1 WO1998046612A1 PCT/US1998/001473 US9801473W WO9846612A1 WO 1998046612 A1 WO1998046612 A1 WO 1998046612A1 US 9801473 W US9801473 W US 9801473W WO 9846612 A1 WO9846612 A1 WO 9846612A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- process according
- formula
- diphenylcyclohexyloxy
- butyl ester
- solvent
- Prior art date
Links
- 0 *C(CC1)CCC1(c1ccccc1)c1ccccc1 Chemical compound *C(CC1)CCC1(c1ccccc1)c1ccccc1 0.000 description 3
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/117—Esters of phosphoric acids with cycloaliphatic alcohols
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/091—Esters of phosphoric acids with hydroxyalkyl compounds with further substituents on alkyl
Definitions
- the present invention relates to an improved process for the production of phosphodiester compounds.
- the invention relates to an improved process for preparing phosphodiester compounds which are useful as contrast agents for diagnostic imaging, and more particularly, for preparing diethylenetriamine- pentaacetic acid ("DTP A") compounds comprising phosphodiesters.
- DTP A diethylenetriamine- pentaacetic acid
- WO 96/23526 describes phosphodiester compounds which are useful as contrast agents for diagnostic imaging
- phosphodiesters One method for making phosphodiesters involves the use of phosphoramidite chemistry. See, e.g., Bannwarth et al., "A Simple and Effective Chemical Phosphorylation Procedure for Biomolecules," Helvetica Chimica Acta. vol. 70, pp. 175-186 (1987); Bannwarth et al., "Bis(allyloxy)(diisopropylamino) phosphine as a New Phosphinylation Reagant of the Phosphorylation of Hydroxy Functions," Tetrahedron Letters, vol. 30, no. 32, pp.
- phosphoramidite methods suffer from the fact that the phosphoramidites are typically unstable compounds (both chemically and kinetically) and upon purification by distillation may ignite or cause an explosion. Further, phosphoramidite methods are generally not suitable for manufacturing phosphodiester compounds on a commercial basis. This is so because the phosphoramidite starting materials are very expensive and are not readily available, and because methods using phosphoramidites tend to involve additional process steps (e.g., additional step of cleaving protecting groups after phosphorylation) as well as multiple isolation and/or purification steps of the intermediates.
- the present invention relates to a safer, more efficient and less expensive process for prepa ⁇ ng phosphodiester compounds, and more particularly, phosphodiesters having the formula
- step (b) coupling of said dichlorophosphine with an amine base to obtain a b ⁇ s(am ⁇ no)phosph ⁇ no
- step (c) coupling of said b ⁇ s(ammo)phosph ⁇ no with a second alcohol, which can be the same or different from that alcohol used in step (a), to obtain a disubstituted (am ⁇ no)phosph ⁇ no
- the process according to this invention avoids the use of unstable phosphorylating agents as well as the need for using a protecting group or a coupling agent
- the present method avoids unnecessary process steps such as deprotection and coupling reagent syntheses
- the phosphodiester synthetic process takes place in one reaction vessel, avoidmg the need for multiple isolation and/or pu ⁇ fication steps Detailed Description of the Invention
- the present invention provides an improved process for preparing phosphodiester compounds of general formula:
- R and R can be the same or different and are selected from the group consisting of linear, branched, or cyclic aliphatic, aryl, heterocyclic, peptidic, peptoid, deoxyribo- or ribo-nucleotidic or nucleosidic, or cyclic or acyclic organic chelating agent groups, all of which may optionally be substituted with one or more nitrogen, oxygen, sulfur, halogen, aliphatic, amide, ester, sulfonamide, aryl, acyl, sulfonate, phosphate, hydroxyl, or organometallic substituents.
- all synthetic steps are performed in one reaction vessel, precluding the need for multiple isolation and/or purification steps.
- the present invention demonstrates an efficient and high-yielding process for producing phosphodiester compounds which does not rely on expensive or unstable starting materials and does not require the use of either protecting groups or coupling agents. Moreover, said process is efficient for the generation of phosphodiester linkages between a wide variety of substituents.
- an alcohol ROH where R has the same meaning as stated above, is reacted with PC1 3 , preferably at a molar ratio of 1 1, to form a dichlorophosphine reaction product (I)
- the solvent may be any ethereal or hydrocarbon solvent and preferably, may be selected from the group consisting of heptanes, methyl-t-butyl ethers, tetrahydrofurans, diethyl ethers, and ethylene glycol dialkyl ethers More preferably, the solvent is tetrahydrofuran
- dichlorophosphine (I) is then reacted with from about 5 to about 6 equivalents of an amine base to form a b ⁇ s(am ⁇ no)phosph ⁇ no reaction product (II)
- reaction product (II) may be any amine b ⁇ se, preferably a base having a pKa value of from about 5 to about 11, and more preferably selected from the group consisting of lmidazole, 2,4-d ⁇ methyhm ⁇ dazole, lH-tetrazole, dialkylamines (methyl, ethyl, butyl), pyndine, piperazme, pipendine, pyrrole, 1H-1, 2, 3-t ⁇ azole, and 1,2,4- t ⁇ azole
- the base is lmidazole
- the solvent may be any ethereal or hydrocarbon solvent and preferably may be selected from the group consisting of heptanes, methyl-t-butyl ethers, dioxanes, tetrahydrofurans, 1,3-d ⁇ oxolanes, diglymes, diethyl ethers, dialkvl ethers, and ethylene glycol dialkyl ethers More preferably, the solvent is tetrahvdrofuran Finally, the (am ⁇ no)phosphmo compound (III) is reacted with about one equivalent of acidic water, preferably having a pH of about 2 5 to about 5, and about 1 or more equivalents of an oxid
- the oxidant may be any peroxide type oxidant and preferably selected from the group consisting of pe ⁇ odates More preferably, the oxidant is sodium pe ⁇ odate
- the above hydrolysis and oxidation is carried out in a solvent mixture at a temperature of from about -15°C to about 25 °C, preferably from about 0°C to about 2°C, for a period of from about 10 to about 24 hours, preferably from about 10 to about 15 hours.
- the solvent mixture comprises any combination of solvents selected from the group consisting of ethereal or hydrocarbon solvents.
- the solvent mixture comprises tetrahydrofuran, heptane and toluene in the volume ratio of 10: 10.1
- phosphodiester contrast agents that may be prepared by this improved process include the compounds shown below, as well as others described in PCT publication no. WO 96/23526
- m l ast one of the two alcohols (ROH, R OH) as defined herein further compnse a cyclic or acyclic organic chelating ligand, with any sensitive functional groups (e.g., carboxylates) on such a chelate protected with appropriate groups (e.g., t-butyl groups)
- Suitable chelating ligands are well known in the art
- preferred chelating ligands include
- the alcohol may comprise a moiety designed to facilitate localization of the resultant agent to the tissue, cell, protein, receptor or area desired to be imaged.
- moieties include lipophilic or amphiphilic substances, receptor ligands, antibodies, or antibody fragments, peptides, or other biomolecules that are known to concentrate in the specific biological component desired to be imaged
Abstract
Description
Claims
Priority Applications (17)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU60425/98A AU728902B2 (en) | 1997-04-11 | 1998-01-27 | Process for synthesizing phosphodiesters |
DK98903734T DK1021452T3 (en) | 1997-04-11 | 1998-01-27 | Process for the Synthesis of Phosphodiesters |
SK1382-99A SK283832B6 (en) | 1997-04-11 | 1998-01-27 | Process for synthesising phosphodiesters |
KR1019997009256A KR100593650B1 (en) | 1997-04-11 | 1998-01-27 | Process for synthesizing phosphodiesters |
AT98903734T ATE236171T1 (en) | 1997-04-11 | 1998-01-27 | METHOD FOR PRODUCING PHOSPHODIESTERS |
PL98337423A PL188258B1 (en) | 1997-04-11 | 1998-01-27 | Method of obtaining phosphodiesters |
HU0004239A HU224257B1 (en) | 1997-04-11 | 1998-01-27 | Process for synthesizing phosphodiesters |
BRPI9809084-4A BR9809084B1 (en) | 1997-04-11 | 1998-01-27 | process for synthesizing phosphodiesters. |
EP98903734A EP1021452B1 (en) | 1997-04-11 | 1998-01-27 | Process for synthesizing phosphodiesters |
JP54386798A JP4014231B2 (en) | 1997-04-11 | 1998-01-27 | Process for the synthesis of phosphodiesters |
CA002285417A CA2285417C (en) | 1997-04-11 | 1998-01-27 | Process for synthesizing phosphodiesters |
DE69812983T DE69812983T2 (en) | 1997-04-11 | 1998-01-27 | METHOD FOR PRODUCING PHOSPHODIA STAR |
IL13196498A IL131964A (en) | 1997-04-11 | 1998-01-27 | Process for preparing phosphodiester compounds |
SI9830426T SI1021452T1 (en) | 1997-04-11 | 1998-01-27 | Process for synthesizing phosphodiesters |
NZ337921A NZ337921A (en) | 1997-04-11 | 1998-01-27 | Process for synthesizing phosphodiesters via a bis (amino) phophino intermediate |
IS5193A IS1994B (en) | 1997-04-11 | 1999-09-24 | Phosphodiester making process |
NO19994919A NO325619B1 (en) | 1997-04-11 | 1999-10-08 | Process for the synthesis of phosphodiester compounds |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/833,745 | 1997-04-11 | ||
US08/833,745 US5919967A (en) | 1997-04-11 | 1997-04-11 | Process for synthesizing phosphodiesters |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1998046612A1 true WO1998046612A1 (en) | 1998-10-22 |
Family
ID=25265165
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1998/001473 WO1998046612A1 (en) | 1997-04-11 | 1998-01-27 | Process for synthesizing phosphodiesters |
Country Status (21)
Country | Link |
---|---|
US (1) | US5919967A (en) |
EP (1) | EP1021452B1 (en) |
JP (2) | JP4014231B2 (en) |
KR (2) | KR20060066122A (en) |
AT (1) | ATE236171T1 (en) |
AU (1) | AU728902B2 (en) |
BR (1) | BR9809084B1 (en) |
CA (1) | CA2285417C (en) |
CZ (1) | CZ294469B6 (en) |
DE (1) | DE69812983T2 (en) |
DK (1) | DK1021452T3 (en) |
ES (1) | ES2195315T3 (en) |
HU (1) | HU224257B1 (en) |
IL (1) | IL131964A (en) |
IS (1) | IS1994B (en) |
NO (1) | NO325619B1 (en) |
NZ (1) | NZ337921A (en) |
PL (1) | PL188258B1 (en) |
PT (1) | PT1021452E (en) |
SK (1) | SK283832B6 (en) |
WO (1) | WO1998046612A1 (en) |
Cited By (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003029257A1 (en) * | 2001-09-27 | 2003-04-10 | Schering Aktiengesellschaft | (ethylene)-(propene/butene)-phosphodiester triamine pentaacetic acid derivatives |
CN100341883C (en) * | 1999-09-09 | 2007-10-10 | 舍林股份公司 | Calcium complex of phosphorus contg. ethylenediamine derivs. |
EP1944312A1 (en) | 2003-03-03 | 2008-07-16 | Dyax Corporation | Peptides that specifically bind HGF receptor (CMET) and uses thereof |
EP2014310A2 (en) | 2002-03-01 | 2009-01-14 | Dyax Corporation | KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy |
US9056138B2 (en) | 2002-03-01 | 2015-06-16 | Bracco Suisse Sa | Multivalent constructs for therapeutic and diagnostic applications |
US9200017B2 (en) | 2009-03-19 | 2015-12-01 | The General Hospital Corporation | Multimodal imaging of fibrin |
US9295737B2 (en) | 2002-03-01 | 2016-03-29 | Bracco Suisse Sa | Targeting vector-phospholipid conjugates |
US9408926B2 (en) | 2002-03-01 | 2016-08-09 | Bracco Suisse S.A. | KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy |
US9446155B2 (en) | 2002-03-01 | 2016-09-20 | Bracco Suisse Sa | KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy |
US9889213B2 (en) | 2009-04-17 | 2018-02-13 | The General Hospital Corporation | Multimodal imaging of fibrin |
US9913875B2 (en) | 2015-03-16 | 2018-03-13 | California Institute Of Technology | Botulinum neurotoxin-specific capture agents, compositions, and methods of using and making |
US10471162B2 (en) | 2014-06-20 | 2019-11-12 | The General Hospital Corporation | Collagen targeted imaging probes |
US10598671B2 (en) | 2015-07-15 | 2020-03-24 | Indi Molecular, Inc. | IL-17F-specific capture agents, compositions, and methods of using and making |
US10975123B2 (en) | 2014-05-05 | 2021-04-13 | California Institute Of Technology | Mutant Akt-specific capture agents, compositions, and methods of using and making |
US11358982B2 (en) | 2016-11-01 | 2022-06-14 | Ohio State Innovation Foundation | Methods for the iodination of biomolecules |
US11414460B2 (en) | 2019-07-19 | 2022-08-16 | Institute For Systems Biology | KRAS-specific capture agents, compositions, and methods of making and using |
US11638764B2 (en) | 2018-11-08 | 2023-05-02 | Indi Molecular, Inc. | Theranostic capture agents, compositions, and methods of using and making |
US11719705B2 (en) | 2017-06-15 | 2023-08-08 | Indi Molecular, Inc. | IL-17F and IL-17A-specific capture agents, compositions, and methods of using and making |
US11733246B2 (en) | 2020-11-03 | 2023-08-22 | Indi Molecular, Inc. | Compositions, imaging, and therapeutic methods targeting folate receptor 1 (FOLR1) |
US11766414B2 (en) | 2020-11-03 | 2023-09-26 | Indi Molecular, Inc. | Compositions, delivery systems, and methods useful in tumor therapy |
US11884707B2 (en) | 2016-09-29 | 2024-01-30 | Regeneron Pharmaceuticals, Inc. | Compositions for detection, inhibition and imaging of indoleamine 2, 3-dioxygenase 1 (IDO1) and methods of making and using same |
US11919972B2 (en) | 2018-11-02 | 2024-03-05 | Regeneron Pharmaceuticals, Inc. | Peptide libraries with non-canonical amino acids |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1019094B1 (en) * | 1997-10-02 | 2003-11-19 | Epix Medical, Inc. | Contrast-enhanced diagnostic imaging method for monitoring interventional therapies |
US20030203879A1 (en) * | 1999-09-09 | 2003-10-30 | Schering Ag | Calcium complex of [[(4R)-4-[bis[(carboxy-.kappa.O)methyl]amino-.kappa.n]-6,9-bis[(carboxy.kappa.O)methyl]-1-[(4,4-diphenylcyclohexy)oxy]-1-hydroxy-2-oxa-6,9-diaza-1-phosphaundecan-11-ylic-acid-.kappa.N6,.Kappa.N9,.Kappa 011]1-oxidato(6-)]-, hexahydrogen, its salts, pharmaceutical agents that contain these complexes, their use in treatment and as additives in diagnosis, as well as processes for the production of the complexes and agents |
US6559330B1 (en) * | 1999-09-09 | 2003-05-06 | Schering Aktiengesellschaft | Calcium complex of [[(4r)-4-[bis{carboxy-.kappa.o)methyl]amino-.kappa.n]-6,9-bis[(carboxy.kappa.o)methyl]-1-[(4,4-diphenylcyclohexyl)oxy]-1-hydroxy-2-oxa-6,9-diaza-1-phosphaundecan-11-ylic-acid-.kappa.n6,.kappa.n9,.kappa.011]1-oxidato(6-)]-, hexahydrogen, its salts, pharmaceutical agents that contain these complexes, their use in treatment and as additives in diagnosis, as well as processes for the production of the complexes and agents |
KR100585219B1 (en) * | 2004-05-07 | 2006-06-01 | 주식회사 태평양 | Derivatives of Phosphate and the method for the preparation thereof |
CN100487093C (en) * | 2006-03-15 | 2009-05-13 | 中国石油化工股份有限公司 | Phosphamide ester extreme pressure anti-wear additives and preparation and application thereof |
TW201514188A (en) * | 2013-03-13 | 2015-04-16 | Lantheus Medical Imaging Inc | Process for manufacture of gadofosveset trisodium monohydrate |
CN116917301A (en) * | 2021-03-03 | 2023-10-20 | 国立大学法人东京工业大学 | Method for producing asymmetric phosphotriester, method for producing symmetric phosphotriester, method for producing phosphate, and method for producing organic phosphorus compound |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996023526A2 (en) * | 1995-02-01 | 1996-08-08 | Epix Medical, Inc. | Diagnostic imaging contrast agents with extended blood retention |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4647447A (en) * | 1981-07-24 | 1987-03-03 | Schering Aktiengesellschaft | Diagnostic media |
US4880008A (en) * | 1985-05-08 | 1989-11-14 | The General Hospital Corporation | Vivo enhancement of NMR relaxivity |
AU717099B2 (en) * | 1995-03-08 | 2000-03-16 | Scripps Research Institute, The | Carbopeptoids and carbonucleotoids |
-
1997
- 1997-04-11 US US08/833,745 patent/US5919967A/en not_active Expired - Lifetime
-
1998
- 1998-01-27 PL PL98337423A patent/PL188258B1/en not_active IP Right Cessation
- 1998-01-27 IL IL13196498A patent/IL131964A/en not_active IP Right Cessation
- 1998-01-27 EP EP98903734A patent/EP1021452B1/en not_active Expired - Lifetime
- 1998-01-27 SK SK1382-99A patent/SK283832B6/en not_active IP Right Cessation
- 1998-01-27 PT PT98903734T patent/PT1021452E/en unknown
- 1998-01-27 KR KR1020067007449A patent/KR20060066122A/en not_active Application Discontinuation
- 1998-01-27 NZ NZ337921A patent/NZ337921A/en not_active IP Right Cessation
- 1998-01-27 DK DK98903734T patent/DK1021452T3/en active
- 1998-01-27 AT AT98903734T patent/ATE236171T1/en active
- 1998-01-27 KR KR1019997009256A patent/KR100593650B1/en not_active IP Right Cessation
- 1998-01-27 ES ES98903734T patent/ES2195315T3/en not_active Expired - Lifetime
- 1998-01-27 CA CA002285417A patent/CA2285417C/en not_active Expired - Lifetime
- 1998-01-27 WO PCT/US1998/001473 patent/WO1998046612A1/en not_active Application Discontinuation
- 1998-01-27 DE DE69812983T patent/DE69812983T2/en not_active Expired - Lifetime
- 1998-01-27 AU AU60425/98A patent/AU728902B2/en not_active Ceased
- 1998-01-27 JP JP54386798A patent/JP4014231B2/en not_active Expired - Fee Related
- 1998-01-27 BR BRPI9809084-4A patent/BR9809084B1/en not_active IP Right Cessation
- 1998-01-27 CZ CZ19993559A patent/CZ294469B6/en not_active IP Right Cessation
- 1998-01-27 HU HU0004239A patent/HU224257B1/en not_active IP Right Cessation
-
1999
- 1999-09-24 IS IS5193A patent/IS1994B/en unknown
- 1999-10-08 NO NO19994919A patent/NO325619B1/en not_active IP Right Cessation
-
2005
- 2005-02-21 JP JP2005044872A patent/JP2005206605A/en not_active Withdrawn
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996023526A2 (en) * | 1995-02-01 | 1996-08-08 | Epix Medical, Inc. | Diagnostic imaging contrast agents with extended blood retention |
Non-Patent Citations (2)
Title |
---|
HENGGE A C ET AL: "Studies of Transition-State Structures in Phosphoryl Transfer Reactions of Phosphodiesters of p-Nitrophenol", J. AM. CHEM. SOC. (JACSAT,00027863);95; VOL.117 (22); PP.5919-26, UNIVERSITY OF WISCONSIN;DEPARTMENT OF BIOCHEMISTRY; MADISON; 53705; WI; USA (US), XP002064885 * |
LU Y ET AL: "A new, convenient and efficient procedure for the synthesis of phosphodiesters using chloro-N,N-diisopropylaminoalkyloxyphosphines", SYNTH. COMMUN. (SYNCAV,00397911);93; VOL.23 (14); PP.1943-6, EC. NATL. SUPER. CHIM. PARIS;LAB. BIOORG. BIOTECHNOL.; PARIS; 75231; FR. (FR), XP002064886 * |
Cited By (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100341883C (en) * | 1999-09-09 | 2007-10-10 | 舍林股份公司 | Calcium complex of phosphorus contg. ethylenediamine derivs. |
WO2003029257A1 (en) * | 2001-09-27 | 2003-04-10 | Schering Aktiengesellschaft | (ethylene)-(propene/butene)-phosphodiester triamine pentaacetic acid derivatives |
US9295737B2 (en) | 2002-03-01 | 2016-03-29 | Bracco Suisse Sa | Targeting vector-phospholipid conjugates |
EP2014310A2 (en) | 2002-03-01 | 2009-01-14 | Dyax Corporation | KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy |
US9056138B2 (en) | 2002-03-01 | 2015-06-16 | Bracco Suisse Sa | Multivalent constructs for therapeutic and diagnostic applications |
US9381258B2 (en) | 2002-03-01 | 2016-07-05 | Bracco Suisse S.A. | Targeting vector-phospholipid conjugates |
US9408926B2 (en) | 2002-03-01 | 2016-08-09 | Bracco Suisse S.A. | KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy |
US9446155B2 (en) | 2002-03-01 | 2016-09-20 | Bracco Suisse Sa | KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy |
US9629934B2 (en) | 2002-03-01 | 2017-04-25 | Dyax Corp. | KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy |
EP1944312A1 (en) | 2003-03-03 | 2008-07-16 | Dyax Corporation | Peptides that specifically bind HGF receptor (CMET) and uses thereof |
US9200017B2 (en) | 2009-03-19 | 2015-12-01 | The General Hospital Corporation | Multimodal imaging of fibrin |
US9889213B2 (en) | 2009-04-17 | 2018-02-13 | The General Hospital Corporation | Multimodal imaging of fibrin |
US10975123B2 (en) | 2014-05-05 | 2021-04-13 | California Institute Of Technology | Mutant Akt-specific capture agents, compositions, and methods of using and making |
US10471162B2 (en) | 2014-06-20 | 2019-11-12 | The General Hospital Corporation | Collagen targeted imaging probes |
US9913875B2 (en) | 2015-03-16 | 2018-03-13 | California Institute Of Technology | Botulinum neurotoxin-specific capture agents, compositions, and methods of using and making |
US11007245B2 (en) | 2015-03-16 | 2021-05-18 | Indi Molecular, Inc. | Botulinum neurotoxin-specific capture agents, compositions, and methods of using and making |
US11723944B2 (en) | 2015-03-16 | 2023-08-15 | Indi Molecular, Inc. | Botulinum neurotoxin-specific capture agents, compositions, and methods of using and making |
US10598671B2 (en) | 2015-07-15 | 2020-03-24 | Indi Molecular, Inc. | IL-17F-specific capture agents, compositions, and methods of using and making |
US11884707B2 (en) | 2016-09-29 | 2024-01-30 | Regeneron Pharmaceuticals, Inc. | Compositions for detection, inhibition and imaging of indoleamine 2, 3-dioxygenase 1 (IDO1) and methods of making and using same |
US11358982B2 (en) | 2016-11-01 | 2022-06-14 | Ohio State Innovation Foundation | Methods for the iodination of biomolecules |
US11719705B2 (en) | 2017-06-15 | 2023-08-08 | Indi Molecular, Inc. | IL-17F and IL-17A-specific capture agents, compositions, and methods of using and making |
US11919972B2 (en) | 2018-11-02 | 2024-03-05 | Regeneron Pharmaceuticals, Inc. | Peptide libraries with non-canonical amino acids |
US11638764B2 (en) | 2018-11-08 | 2023-05-02 | Indi Molecular, Inc. | Theranostic capture agents, compositions, and methods of using and making |
US11414460B2 (en) | 2019-07-19 | 2022-08-16 | Institute For Systems Biology | KRAS-specific capture agents, compositions, and methods of making and using |
US11733246B2 (en) | 2020-11-03 | 2023-08-22 | Indi Molecular, Inc. | Compositions, imaging, and therapeutic methods targeting folate receptor 1 (FOLR1) |
US11766414B2 (en) | 2020-11-03 | 2023-09-26 | Indi Molecular, Inc. | Compositions, delivery systems, and methods useful in tumor therapy |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1021452B1 (en) | Process for synthesizing phosphodiesters | |
KR100311560B1 (en) | Method for preparing aza macrocyclic or acyclic aminophosphonate ester derivatives | |
JPH06506485A (en) | phosphorus compounds | |
EP1370565B1 (en) | Method of producing 1-hydroxy-1,1-diphosphonic acid compounds | |
MXPA99009219A (en) | Process for synthesizing phosphodiesters | |
CZ258595A3 (en) | Process for preparing aminomethanephosphonic acid | |
Breuer et al. | Synthesis and reactions of 2, 2, 2‐trihaloethyl α‐hydroxyiminobenzylphosphonates. The influence of the ester group on the chemistry of phosphonates | |
JP2511706B2 (en) | Phosphate ester | |
JP2673605B2 (en) | Phosphorylating agent and phosphodiester bond forming method using the same | |
Macomber et al. | Reactions of oxaphospholenes. 2. Hydrolysis of neopentyl esters, phenyl esters, and amides | |
RU2126413C1 (en) | Phospholipid derivatives, a method of their synthesis, a pharmaceutical composition based on said, methods of a pharmaceutical composition preparing | |
KR100323842B1 (en) | Process for producing (meth)acrylate derivatives | |
US20090062567A1 (en) | Bis(phosphine) boronium salt, production method of bis(phosphine) boronium salt, and bis(phosphine) boronium salt produced by the production method |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 131964 Country of ref document: IL |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 60425/98 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 337921 Country of ref document: NZ |
|
ENP | Entry into the national phase |
Ref document number: 2285417 Country of ref document: CA Kind code of ref document: A Ref document number: 2285417 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: PV1999-3559 Country of ref document: CZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/1999/009219 Country of ref document: MX Ref document number: 138299 Country of ref document: SK Ref document number: 1019997009256 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1998903734 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: PV1999-3559 Country of ref document: CZ |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 1998903734 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1019997009256 Country of ref document: KR |
|
WWG | Wipo information: grant in national office |
Ref document number: 60425/98 Country of ref document: AU |
|
WWG | Wipo information: grant in national office |
Ref document number: 1998903734 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: PV1999-3559 Country of ref document: CZ |
|
WWR | Wipo information: refused in national office |
Ref document number: 1019997009256 Country of ref document: KR |